首页> 外文期刊>European review for medical and pharmacological sciences. >Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma
【24h】

Expressions of MiR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus-related hepatocellular carcinoma

机译:MiR-132在慢性乙型肝炎,肝炎后肝硬化和乙型肝炎病毒相关的肝细胞癌患者中的表达

获取原文
           

摘要

OBJECTIVE: To explore the expressions of miR-132 in patients with chronic hepatitis B, posthepatitic cirrhosis and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), and to investigate its possible mechanism affecting the function of the body. PATIENTS AND METHODS: Among 125 patients with HBV, there were 44 cases of chronic hepatitis, 42 cases of liver cirrhosis and 39 cases of liver cancer. Their liver function and HBV-deoxyribonucleic acid (HBV-DNA) viral load as well as the expressions of micro ribonucleic acid-132 (miR-132), phosphoinositide 3-kinase (PI3K), phosphorylated-protein kinase B (p-Akt) and hepatitis B X protein (HBx), were detected. RESULTS: There were significant differences in some liver function indexes and the HBV-DNA level among the three groups of patients (p 0.05). The HBV-DNA level was 6.91 Lg copies/mL in the liver cancer group and 5.34 Lg copies/mL in the chronic hepatitis B group. Differences in the expression level of miR-132 among the three groups were notable (p 0.05), but this expression level had a negative correlation with the HBV-DNA level. The expressions of PI3K and p-Akt proteins and messenger ribonucleic acids (mRNAs) were markedly different among the three groups (p 0.05). HBx was expressed in the three groups of patients, and liver cancer patients with the highest expression degree of HBx accounted for 46%. CONCLUSIONS: Differences in the expression of miR-132 among the three groups are evident, which may be associated with differences in liver function, the HBV-DNA level, HBx and the expressions of PI3K and p-Akt proteins to a certain degree.
机译:目的:探讨miR-132在慢性乙型肝炎,肝炎后肝硬化和乙型肝炎病毒(HBV)相关的肝细胞癌(HCC)患者中的表达,并探讨其可能影响机体功能的机制。病人和方法:在125例HBV患者中,有44例慢性肝炎,42例肝硬化和39例肝癌。它们的肝功能和HBV-脱氧核糖核酸(HBV-DNA)病毒载量以及微核糖核酸132(miR-132),磷酸肌醇3激酶(PI3K),磷酸化蛋白激酶B(p-Akt)的表达并检测到肝炎BX蛋白(HBx)。结果:三组患者的某些肝功能指标和HBV-DNA水平存在显着差异(p <0.05)。肝癌组的HBV-DNA水平为6.91 Lg拷贝/ mL,慢性乙型肝炎组为5.34 Lg拷贝/ mL。三组中miR-132的表达水平差异显着(p <0.05),但该表达水平与HBV-DNA水平呈负相关。三组之间PI3K和p-Akt蛋白以及信使核糖核酸(mRNA)的表达差异显着(p <0.05)。 HBx在三组患者中表达,其中HBx表达程度最高的肝癌患者占46%。结论:三组间miR-132的表达存在明显差异,在一定程度上可能与肝功能,HBV-DNA水平,HBx以及PI3K和p-Akt蛋白的表达有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号